Oncology News | pharmaphorum

News

FDA approves Roche's $90,000 lymphoma combination

The FDA has quickly approved a new antibody treatment for an aggressive form of lymphoma from Roche – costing in the region of $90,000 for a four-month course.

News

AstraZeneca ends another Calquence trial early

For the second time in the space of a month AstraZeneca has stopped a trial of its chronic lymphocytic leukaemia (CLL) drug Calquence (acalabrutinib) early following positive results.

News

Gilead highlights Yescarta survival data in ASCO update

Gilead’s Kite subsidiary has reported new data from the main trial for its CAR-T Yescarta, hoping to encourage greater use of the slow-growing therapy. Updated results from the ZUM

News

Relax criteria to increase sign-ups to cancer trials, says A...

Only 3% of patients with cancer in the US enrol on a clinical trial – and the American Society of Clinical Oncology (ASCO) is concerned that outdated and restrictive eligibility criteria co

News

AZ/Merck & Co wow ASCO with pancreatic cancer data

Finding targeted therapies for pancreatic cancer has long been an issue for pharma, meaning that for decades the only real option has been a course of chemotherapy, with unpleasant side-eff

News

Radiology technician examens mammography test on location

MacroGenics looks to future with breast cancer drug margetux...

A small biotech, MacroGenics, took the market by surprise earlier this year with some surprising data from its margetuximab – essentially a tweaked version of Roche’s Herceptin (trastuzumab

FDA approves Roche's $90,000 lymphoma combination

AstraZeneca ends another Calquence trial early

Gilead highlights Yescarta survival data in ASCO update

Relax criteria to increase sign-ups to cancer trials, says A...

AZ/Merck & Co wow ASCO with pancreatic cancer data

MacroGenics looks to future with breast cancer drug margetux...

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks